Elevance Health (NYSE:ELV) Price Target Raised to $406.00

Posted by Geri Gentry on Oct 25th, 2026

Elevance Health (NYSE:ELV – Free Report) had its price objective boosted by Robert W. Baird from $393.00 to $406.00 in a research note issued to investors on Thursday, Marketbeat.com reports. Robert W. Baird currently has a neutral rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Guggenheim increased their price target on Elevance Health from $455.00 to $460.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Elevance Health in a research note on Thursday, August 13th. Raymond James Financial set a $450.00 target price on Elevance Health in a report on Tuesday, July 7th. Finally, Cantor Fitzgerald increased their target price on shares of Elevance Health from $400.00 to $450.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and a consensus price target of $455.57.

Get Our Latest Stock Analysis on ELV

Elevance Health Price Performance

Shares of NYSE:ELV opened at $440.05 on Thursday. The firm has a market cap of $95.08 billion, a PE ratio of 18.77, a price-to-earnings-growth ratio of 2.30 and a beta of 0.70. The firm’s fifty day moving average is $408.32 and its 200-day moving average is $390.89. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.47. Elevance Health has a 52 week low of $274.84 and a 52 week high of $450.69.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, topping the consensus estimate of $4.71 by $2.28. The company had revenue of $50.44 billion for the quarter, compared to analysts’ expectations of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. Elevance Health’s revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.03 earnings per share. Sell-side analysts predict that Elevance Health will post 29.11 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s payout ratio is currently 29.34%.

Insider Activity at Elevance Health

In related news, CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the sale, the chief financial officer owned 19,919 shares of the company’s stock, valued at $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.34% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Elevance Health

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Elevance Health in the 2nd quarter valued at about $7,344,424,000. Bank of New York Mellon Corp acquired a new position in Elevance Health during the 2nd quarter valued at about $1,246,349,000. Legal & General Group Plc acquired a new position in Elevance Health during the 2nd quarter valued at about $688,469,000. Amundi increased its holdings in Elevance Health by 145.7% during the 1st quarter. Amundi now owns 2,693,664 shares of the company’s stock worth $788,570,000 after purchasing an additional 1,597,497 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Elevance Health during the 2nd quarter worth approximately $591,084,000. 89.24% of the stock is owned by institutional investors and hedge funds.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

About Elevance Health

(Get Free Report)

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.